Regeneron Pharmaceuticals Achieves Record 2024 Performance

Regeneron Pharmaceuticals 2024 Financial Highlights

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has unveiled its financial results for the fourth quarter and full year 2024, showcasing remarkable growth and a strong commitment to its shareholders. The fourth quarter revenues rose by an impressive 10%, reaching $3.79 billion compared to the same period last year.

Full Year Financial Overview

The company reported full year revenues of $14.20 billion, marking an 8% increase from 2023. When excluding the impact of Ronapreve, the revenue increase was even more significant at 10%. This growth trajectory highlights Regeneron's resilience and the robust demand for its flagship products.

Quarterly Sales Update

Record Sales for Dupixent

One of the standout performers was Dupixent, with global net sales recorded by Sanofi jumping 15% to $3.70 billion in the fourth quarter, while full year sales reached $14.15 billion, up 22% from 2023. This figure underscores Dupixent's pivotal role in Regeneron's portfolio, firmly establishing it as a leader in the treatment of various allergic and inflammatory conditions.

EYLEA Performance

Sales of EYLEA continued to show stability with U.S. net sales for both EYLEA HD and EYLEA increasing 2% compared to last year to reach $1.50 billion in Q4. The total sales for the fiscal year were reported at $5.97 billion, a 1% increase from 2023. EYLEA HD, a newer addition to the lineup, contributed significantly to this revenue growth, indicating successful market penetration and acceptance.

Libtayo and Other Treatments

The fourth quarter also saw Libtayo's global net sales swell by 50% to $367 million, and annual sales reached $1.22 billion, representing a 40% increase year-over-year. This strong performance in oncology reflects Regeneron’s ongoing commitment to addressing critical unmet medical needs.

Dividend Announcement and Share Repurchase Program

As part of its shareholder return strategy, Regeneron announced the initiation of a quarterly cash dividend program with a declared amount of $0.88 per share. In addition, the company has authorized a new share repurchase program worth $3.0 billion, augmenting its total buyback capacity to approximately $4.5 billion. This move demonstrates Regeneron's robust financial health and commitment to providing value to its investors.

Regulatory and R&D Advances

Regeneron is making strides with several regulatory applications, including those for EYLEA HD pre-filled syringes, Dupixent for treating bullous pemphigoid, and other promising treatments for various cancers. Notably, significant positive Phase 3 results have been reported for both EYLEA HD and Libtayo in clinical settings.

Upcoming Milestones

Looking ahead, Regeneron has a considerable number of anticipated milestones for 2025. These include submissions for the supplemental Biologics License Applications (sBLA) for multiple indications associated with its key products, reflecting a sustained focus on delivering advanced treatments to patients.

Frequently Asked Questions

What were Regeneron’s revenue figures for 2024?

Regeneron reported total revenues of $14.20 billion for the year 2024, showcasing an 8% increase from 2023.

How did Dupixent perform in the last quarter?

Dupixent achieved global net sales of $3.70 billion in the fourth quarter, a 15% increase compared to the same quarter in 2023.

Is there a dividend for Regeneron shareholders?

Yes, Regeneron declared a quarterly cash dividend of $0.88 per share starting in 2025.

What is the future outlook for Regeneron’s products?

Regeneron is actively working on several new indications and has regulatory applications in progress for various therapies. The company anticipates significant milestones in 2025.

Where can investors find more information on Regeneron?

For more details, investors can visit Regeneron's official website and its investor relations page for updates and further information.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.